Related Articles
Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX‑4 chemotherapy
Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX‑4 chemotherapy
FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs
Sulforaphane has an additive anticancer effect to FOLFOX in highly metastatic human colon carcinoma cells